Matthew J. Kraeutler
Patients with early hip osteoarthritis underwent total hip arthroplasty or hip resurfacing at a significantly lower rate after treatment with platelet-rich plasma injections compared with hyaluronic acid, according to results presented at the Arthroscopy Association of North America Annual Meeting.
Matthew J. Kraeutler, MD, and colleagues randomly assigned 32 hips with early OA in 30 patients to receive treatment with either PRP or hyaluronic acid. Researchers collected WOMAC scores and assessed patient-reported outcomes and hip range of motion at baseline and at 6 weeks, 3 months and 6 months after injection.
“In terms of survivorship, significantly more patients who received hyaluronic acid injections withdrew to undergo either total hip arthroplasty or a hip resurfacing procedure compared to patients in the PRP group, 50% vs. 11%,” Kraeutler said in his presentation here.
He added that patients in the PRP group had significant improvements in WOMAC joint, function and overall scores from baseline to 6 weeks. WOMAC joint scores also significantly improved from baseline to 6 months in the PRP group, Kraeutler noted.
“Overall, the PRP [group] demonstrated greater improvement in most of these subscores, but this was not always statistically significant due to a relatively low sample size,” Kraeutler said.
He also noted there were no significant improvements in any of the subscores at any time point in the hyaluronic acid group.
“Finally, looking at range of motion in terms of hip internal rotation, the PRP group demonstrated significantly greater improvement from baseline to 6 months compared to the hyaluronic acid group,” Kraeutler said. “The [hyaluronic acid] HA group actually showed a decline in this outcome from baseline to 6 months.” – by Casey Tingle
Kraeutler MJ, et al. A double-blind, randomized controlled trial comparing platelet-rich plasma vs. hyaluronic acid for early osteoarthritis of the hip joint. Presented at: Arthroscopy Association of North America Annual Meeting; May 2-4, 2019; Orlando.
Disclosure: Kraeutler reports no relevant financial disclosures.